title: New tricks for old dogs: countering antibiotic resistance in tuberculosis with host-directed therapeutics.
abstract: Despite the availability of Mycobacterium tuberculosis (Mtb) drugs for over 50 years, tuberculosis (TB) remains at pandemic levels. New drugs are urgently needed for resistant strains, shortening duration of treatment, and targeting different stages of the disease, especially for treatment during human immunodeficiency virus co-infection. One solution to the conundrum that antibiotics kill the bacillus yet select for resistance is to target the host rather than the pathogen. Here, we discuss recent progress in so-called 'host-directed therapeutics' (HDTs), focusing on two general mechanistic strategies: (i) HDTs that disrupt Mtb pathogenesis in macrophages and (ii) immunomodulatory HDTs that facilitate protective immune responses that kill Mtb or reduce deleterious responses that exacerbate disease. HDTs hold significant promise as adjunctive therapies in that they are less likely to engender resistance, will likely have efficacy against antibiotic-resistant strains, and may have activity against non-replicating Mtb. However, TB is a complex and variegated disease, and human populations exhibit significant diversity in their immune responses to it, which presents a complicated landscape for HDTs to navigate. Nevertheless, we suggest that a detailed mechanistic understanding of drug action, together with careful selection of disease stage targets and dosing strategies may overcome such limitations and allow the development of HDTs as effective adjunctive treatment options for TB.
authors.affiliation: Department of Medicine, University of Washington, Seattle, WA, USA.
authors.forename: Thomas R
authors.initials: TR
authors.lastname: Hawn
authors.forename: Javeed A
authors.initials: JA
authors.lastname: Shah
authors.forename: Daniel
authors.initials: D
authors.lastname: Kalman
mesh_terms: D000818:Animals; D000995:Antitubercular Agents / Q000494:pharmacology* / Q000627:therapeutic use*; D001343:Autophagy; D050260:Carbohydrate Metabolism / Q000187:drug effects; D016207:Cytokines / Q000378:metabolism; D024881:Drug Resistance, Bacterial; D015777:Eicosanoids / Q000378:metabolism; D054884:Host-Pathogen Interactions; D006801:Humans; D007113:Immunity, Innate / Q000187:drug effects; D050356:Lipid Metabolism / Q000187:drug effects; D009169:Mycobacterium tuberculosis / Q000187:drug effects* / Q000502:physiology*; D057285:Precision Medicine; D014376:Tuberculosis / Q000188:drug therapy* / Q000276:immunology / Q000382:microbiology*
chemical_list: D000995:Antitubercular Agents; D016207:Cytokines; D015777:Eicosanoids
keywords: drug; innate immunity; macrophage; tuberculosis